Pituitary Adenoma

Pituitary adenoma is a benign, slow-growing neoplasm arising from the adenohypophyseal (anterior pituitary) cells of the pituitary gland. In veterinary medicine, it is the most common pituitary tumor in dogs and is a frequent cause of hyperadrenocorticism (Cushing's syndrome) due to excessive secretion of adrenocorticotropic hormone (ACTH). Pituitary adenomas can be classified based on their hormonal activity (functional vs. non-functional), size (microadenoma <10 mm, macroadenoma >10 mm), and histologic subtype (chromophobic, basophilic, eosinophilic). Functional adenomas may secrete ACTH, growth hormone (GH), prolactin, or thyroid-stimulating hormone (TSH), leading to distinct endocrinopathies. Non-functional adenomas can cause neurologic signs due to local expansion and compression of surrounding brain structures. The tumor can also cause secondary hypopituitarism by compressing normal pituitary tissue. In cats, pituitary adenomas are less common but can cause acromegaly (GH-secreting) or hyperadrenocorticism (ACTH-secreting).

The exact etiology of pituitary adenomas in veterinary patients remains largely unknown. However, several potential causative factors have been proposed based on human and experimental studies. These include: (1) Genetic mutations: Sporadic somatic mutations in genes such as GNAS (encoding the alpha subunit of G-proteins) have been identified in some human pituitary adenomas, leading to constitutive activation of cAMP signaling. Similar mutations may occur in dogs, though specific evidence is limited. (2) Hypothalamic dysregulation: Chronic overproduction of hypothalamic releasing hormones (e.g., corticotropin-releasing hormone, CRH) may stimulate pituitary cell proliferation, potentially leading to adenoma formation. (3) Growth factors: Overexpression of growth factors such as fibroblast growth factor (FGF) and transforming growth factor-alpha (TGF-alpha) has been implicated in pituitary tumorigenesis. (4) Ionizing radiation: Exposure to radiation is a known risk factor for pituitary tumors in humans, but this is rarely relevant in veterinary patients. (5) Inherited predisposition: Certain dog breeds, such as Boxers, Boston Terriers, and Dachshunds, have a higher incidence of pituitary-dependent hyperadrenocorticism, suggesting a genetic component. (6) Idiopathic: In most cases, no clear etiologic agent is identified, and the tumor arises spontaneously.

Pituitary adenomas are most commonly diagnosed in dogs, with a higher prevalence in middle-aged to older animals (typically 6-12 years of age). There is no strong sex predilection, though some studies suggest a slight female predominance. Certain breeds are overrepresented, including Boxers, Boston Terriers, Dachshunds, Poodles, and German Shepherds. In cats, pituitary adenomas are less common but are increasingly recognized, particularly in older cats (mean age 10-12 years). ACTH-secreting adenomas are the most frequent functional type in dogs, accounting for approximately 80-85% of cases of hyperadrenocorticism. GH-secreting adenomas are rare in dogs but are the most common pituitary tumor in cats, leading to acromegaly. Non-functional adenomas are less common but can be diagnosed incidentally on advanced imaging or at necropsy. The incidence of pituitary adenomas in the general dog population is estimated at 0.1-0.2%, but it is higher in certain breeds. Geographic variation is not well-documented, but the disease is seen worldwide.

Pituitary adenomas arise from clonal expansion of a single transformed cell in the anterior pituitary. The tumor grows slowly and may become functional, secreting excessive hormones. In ACTH-secreting adenomas, chronic hypersecretion of ACTH leads to bilateral adrenal cortical hyperplasia and excessive cortisol production, resulting in hyperadrenocorticism. The negative feedback mechanism is disrupted because the adenoma is partially resistant to glucocorticoid inhibition. In GH-secreting adenomas, excessive GH leads to insulin-like growth factor-1 (IGF-1) production, causing acromegaly, which is characterized by soft tissue and bone proliferation, insulin resistance, and diabetes mellitus. Non-functional adenomas can cause mass effects, compressing the hypothalamus, optic chiasm, and surrounding brain tissue, leading to neurologic signs such as lethargy, behavioral changes, visual deficits, and seizures. Compression of the pituitary stalk can also interfere with dopamine delivery to the pituitary, leading to hyperprolactinemia. Additionally, large adenomas can cause hydrocephalus or brain herniation. The tumor may also invade locally into the cavernous sinus or sphenoid bone, though metastasis is extremely rare.

Predisposing factors for pituitary adenoma development include: (1) Breed: Certain breeds (Boxer, Boston Terrier, Dachshund, Poodle, German Shepherd) have a genetic predisposition. (2) Age: Older animals are more commonly affected, likely due to accumulated genetic mutations over time. (3) Sex: Some studies suggest a slight female predisposition, but this is not consistent. (4) Obesity: Obesity is a risk factor for hyperadrenocorticism, but its role in pituitary tumorigenesis is unclear. (5) Concurrent endocrine disease: Chronic primary hypothyroidism or other endocrine imbalances may increase the risk of pituitary hyperplasia and adenoma formation. (6) Environmental factors: Exposure to certain toxins or endocrine disruptors has been hypothesized but not proven. (7) Iatrogenic: Prolonged use of progestins (e.g., in cats) can lead to GH-secreting pituitary tumors, particularly in cats treated with progestational compounds for dermatologic conditions.

Clinical signs of pituitary adenoma depend on the hormonal activity and size of the tumor. In ACTH-secreting adenomas (pituitary-dependent hyperadrenocorticism), signs include polyuria, polydipsia, polyphagia, abdominal distension (pot-bellied appearance), bilateral symmetrical alopecia, thin skin, comedones, calcinosis cutis, muscle weakness, lethargy, and panting. In cats, signs may include fragile skin, unkempt hair coat, and diabetes mellitus. In GH-secreting adenomas (acromegaly), signs include enlargement of the head, paws, and abdomen, prognathia inferior, respiratory stridor, insulin-resistant diabetes mellitus, and cardiomyopathy. Non-functional adenomas or macroadenomas can cause neurologic signs such as depression, disorientation, head pressing, circling, blindness (due to optic chiasm compression), ataxia, and seizures. In some cases, the tumor may cause hydrocephalus or pituitary apoplexy (hemorrhage), leading to acute onset of neurologic signs. Early signs may be subtle, such as mild lethargy or behavioral changes.

Differential diagnoses for pituitary adenoma include: (1) Adrenal-dependent hyperadrenocorticism (adrenal tumor): Differentiated by ACTH levels (low in adrenal tumors) and imaging (bilateral adrenal enlargement in PDH vs. unilateral mass in adrenal tumor). (2) Functional adrenal tumor (adenoma or carcinoma): Similar clinical signs, but ACTH is suppressed, and ultrasound shows a unilateral adrenal mass. (3) Pituitary carcinoma: Rare, but can cause similar signs; histopathology is needed for definitive diagnosis. (4) Other intracranial neoplasms (meningioma, glioma, lymphoma): May cause neurologic signs but lack endocrine abnormalities; MRI and CSF analysis help differentiate. (5) Hypothalamic-pituitary axis dysfunction due to trauma or inflammation: May cause secondary hypopituitarism; history and imaging are helpful. (6) Ectopic ACTH syndrome (rare): Caused by non-pituitary tumors secreting ACTH; diagnosis is challenging and requires advanced imaging and hormone testing. (7) Diabetes mellitus: Can cause polyuria/polydipsia and polyphagia, but lacks other signs of hyperadrenocorticism; endocrine testing differentiates. (8) Acromegaly due to GH-secreting tumor: In cats, must be differentiated from diabetes mellitus alone; IGF-1 levels are elevated. (9) Psychogenic polydipsia: Causes polyuria/polydipsia but no other endocrine signs; water deprivation test may be needed. (10) Chronic kidney disease: Can cause polyuria/polydipsia and poor hair coat; laboratory findings (azotemia, isosthenuria) differentiate.

The diagnostic approach for suspected pituitary adenoma involves a stepwise algorithm: (1) Initial assessment: Complete history, physical examination, and baseline laboratory tests (CBC, serum biochemistry, urinalysis). (2) Screening for hyperadrenocorticism: If clinical signs suggest Cushing's, perform urine cortisol:creatinine ratio (UCCR) or ACTH stimulation test. A UCCR > 10 (dogs) or > 13 (cats) is suggestive, but confirmatory testing is needed. (3) Confirmatory testing: Low-dose dexamethasone suppression test (LDDST) is the preferred test for PDH; in dogs, cortisol > 1.4 µg/dL at 8 hours post-dexamethasone indicates hyperadrenocorticism. If LDDST is inconclusive, perform ACTH stimulation test. (4) Differentiation of PDH vs. adrenal tumor: Measure endogenous ACTH concentration; in PDH, ACTH is normal to high (> 20 pg/mL), while in adrenal tumor, it is suppressed (< 10 pg/mL). Alternatively, high-dose dexamethasone suppression test (HDDST) can be used; in PDH, > 50% suppression of cortisol is expected, while adrenal tumors show no suppression. (5) Imaging: Abdominal ultrasound to assess adrenal gland size and symmetry; bilateral enlargement suggests PDH, while unilateral mass suggests adrenal tumor. Thoracic radiographs to check for metastasis if adrenal tumor is suspected. (6) Advanced imaging: MRI or CT of the brain to visualize the pituitary gland; a contrast-enhancing mass in the pituitary region is consistent with adenoma. MRI is superior for soft tissue detail and detection of macroadenomas. (7) Histopathology: If surgery or necropsy is performed, histologic examination confirms the diagnosis. (8) Additional tests: For acromegaly in cats, measure serum IGF-1 concentration; elevated levels (> 1000 ng/mL) are suggestive. For non-functional adenomas, endocrine testing may show deficiencies (e.g., low cortisol, low thyroid hormone).

Laboratory findings in pituitary adenoma depend on the hormonal type. In ACTH-secreting adenomas (PDH), CBC may show stress leukogram (neutrophilia, lymphopenia, eosinopenia). Serum biochemistry often reveals elevated alkaline phosphatase (ALP) due to steroid-induced isoenzyme, mild hyperglycemia, hypercholesterolemia, and increased alanine aminotransferase (ALT). Urinalysis may show low urine specific gravity (< 1.020) due to cortisol-induced diuresis, and proteinuria may be present. Endocrine tests: UCCR is elevated (> 10 in dogs, > 13 in cats). LDDST shows failure to suppress cortisol (< 50% suppression from baseline). ACTH stimulation test shows exaggerated cortisol response (> 600 nmol/L in dogs). Endogenous ACTH is normal to high (> 20 pg/mL). In GH-secreting adenomas (acromegaly), IGF-1 is markedly elevated (> 1000 ng/mL in cats). Hyperglycemia and glycosuria are common due to insulin resistance. In non-functional adenomas, there may be deficiencies of pituitary hormones, leading to low cortisol, low T4, and low sex hormones. Additionally, serum sodium may be low if secondary hypoadrenocorticism occurs. In cases of pituitary apoplexy, acute hemorrhage may cause anemia and electrolyte imbalances.

Imaging plays a crucial role in diagnosing pituitary adenomas. Abdominal ultrasound is used to assess adrenal glands; in PDH, both adrenal glands are typically enlarged (dorsoventral thickness > 7.5 mm in dogs) and symmetrical. In adrenal tumors, one gland is enlarged and the other is atrophic. Thoracic radiographs may show metastatic lesions if adrenal carcinoma is suspected. For the pituitary gland, MRI is the gold standard; it reveals a well-defined, contrast-enhancing mass in the region of the pituitary gland. Microadenomas (< 10 mm) may be difficult to visualize, but dynamic contrast-enhanced MRI can improve detection. Macroadenomas (> 10 mm) are easily seen and may cause compression of the hypothalamus, optic chiasm, or third ventricle. CT is also useful, especially for detecting mineralization or bony changes, but MRI provides better soft tissue contrast. In cats with acromegaly, MRI may show a pituitary mass, but some cats have diffuse pituitary enlargement. Advanced imaging is essential for surgical planning and for monitoring tumor progression.

Cytology is rarely used for pituitary adenomas because the tumor is intracranial and not accessible for FNA. However, if a pituitary mass is biopsied during surgery, cytologic smears may show clusters of uniform, round to polygonal cells with moderate cytoplasm and round nuclei. Histopathology is the definitive diagnostic method. On histologic examination, pituitary adenomas are composed of well-differentiated cells arranged in sheets, cords, or acini, with minimal atypia. The cells may be chromophobic, basophilic, or eosinophilic depending on the hormone content. Immunohistochemistry (IHC) can be used to identify the specific hormone produced (e.g., ACTH, GH, prolactin). The tumor is typically encapsulated and may compress adjacent normal pituitary tissue. In contrast, pituitary carcinomas show invasion into surrounding tissues, cellular atypia, and mitotic figures. Special stains such as reticulin stain can help differentiate adenoma (loss of acinar architecture) from hyperplasia (preserved architecture).

Treatment of pituitary adenoma depends on the type and clinical signs. For ACTH-secreting adenomas (PDH), medical therapy is often the first-line treatment. Trilostane (Vetoryl) is the most commonly used drug; the initial dose is 2-5 mg/kg PO q24h, with food. The dose is titrated based on clinical response and ACTH stimulation test results (target post-ACTH cortisol 41-138 nmol/L). Alternatively, mitotane (Lysodren) can be used, but it has more side effects. For cats, trilostane is used at a dose of 2-3 mg/kg PO q24h. For GH-secreting adenomas (acromegaly), treatment is more challenging; surgical removal (hypophysectomy) is the treatment of choice if the tumor is accessible, but it requires specialized equipment and expertise. Radiation therapy (stereotactic or conventional) is an alternative to control tumor growth. Medical management of acromegaly includes insulin therapy for diabetes mellitus, but insulin resistance is common. For non-functional adenomas causing neurologic signs, surgical decompression or radiation therapy may be indicated. Supportive care includes managing concurrent conditions such as hypertension, urinary tract infections, and pancreatitis. In all cases, close monitoring is essential.

The prognosis for pituitary adenoma varies. For ACTH-secreting adenomas treated with trilostane, the median survival time is approximately 2-3 years, with good quality of life if monitored properly. Prognosis is worse if the tumor is a macroadenoma causing neurologic signs; median survival may be less than 6 months without treatment. For cats with acromegaly, the prognosis is guarded; with radiation therapy, median survival can be 1-2 years, but insulin resistance often persists. Surgical hypophysectomy can be curative for microadenomas, but it carries significant risks (e.g., hemorrhage, infection, hypopituitarism) and is only available at specialized centers. Negative prognostic indicators include large tumor size (> 10 mm), presence of neurologic signs, poor response to medical therapy, and concurrent diseases such as diabetes mellitus or pancreatitis. Regular monitoring and dose adjustments can improve outcomes.

Follow-up for pituitary adenoma patients is critical. For dogs on trilostane, re-evaluation should occur at 2 weeks, 4 weeks, and then every 3-6 months. At each visit, perform physical examination, measure electrolytes (especially sodium and potassium), and assess clinical signs. ACTH stimulation test should be performed 4-6 hours after trilostane administration to ensure adequate cortisol suppression. Adjust the dose as needed. For cats on trilostane, similar monitoring is recommended. For patients undergoing radiation therapy, MRI should be repeated every 3-6 months to assess tumor response. For those with neurologic signs, neurologic examinations should be performed regularly. Long-term monitoring includes blood pressure measurement, urine culture, and assessment for complications such as diabetes mellitus or pancreatitis. If the patient is on insulin, blood glucose curves should be performed periodically. For non-functional adenomas, endocrine function should be monitored to detect hypopituitarism, and hormone replacement therapy may be needed.

Pearls: (1) Always confirm hyperadrenocorticism with a low-dose dexamethasone suppression test or ACTH stimulation test before starting treatment. (2) In dogs, a UCCR > 10 is a good screening test, but it can be falsely elevated by stress; repeat if necessary. (3) Trilostane should be given with food to enhance absorption; monitor electrolytes for hyperkalemia. (4) In cats, acromegaly should be suspected in diabetic cats with poor insulin response; measure IGF-1. (5) MRI is essential for detecting macroadenomas; if neurologic signs are present, consider advanced imaging early. Pitfalls: (1) Do not use trilostane in animals with primary hepatic disease or renal insufficiency without dose adjustment. (2) Avoid using mitotane in cats due to severe side effects. (3) Do not perform surgery on large invasive tumors without advanced imaging and surgical expertise. (4) Do not forget to monitor for hypoadrenocorticism during trilostane therapy; signs include lethargy, vomiting, and collapse. (5) Do not rely solely on clinical signs to adjust trilostane dose; use ACTH stimulation test results.

For ACTH-secreting pituitary adenomas (PDH) in dogs: Trilostane (Vetoryl) initial dose 2-5 mg/kg PO q24h with food. After 10-14 days, perform ACTH stimulation test 4-6 hours post-pill; target post-ACTH cortisol 41-138 nmol/L. Adjust dose by 1 mg/kg increments based on response. Maximum dose is typically 15-20 mg/kg/day. Alternative: Mitotane (Lysodren) for dogs: Induction phase 50 mg/kg/day PO divided q12h for 5-7 days, until cortisol < 40 nmol/L on ACTH stimulation test; maintenance dose 50 mg/kg/week divided q12h. For cats: Trilostane 2-3 mg/kg PO q24h; adjust based on clinical signs and cortisol levels. For GH-secreting adenomas (acromegaly): No specific medical therapy; treat diabetes mellitus with insulin (e.g., glargine or detemir) at 0.5-1 U/kg SC q12h, titrated based on glucose curves. For non-functional adenomas causing neurologic signs: Prednisone 0.5-1 mg/kg PO q24h may reduce peritumoral edema. For radiation therapy, use stereotactic radiation (e.g., 3-5 fractions of 8-10 Gy) or conventional fractionated radiation (total dose 48-54 Gy in 16-18 fractions). Always monitor for side effects and adjust doses based on organ function.

Key studies and consensus guidelines: (1) ACVIM consensus statement on the diagnosis and treatment of hyperadrenocorticism in dogs (2012) recommends trilostane as first-line therapy for PDH. (2) A study by Braddock et al. (2003) reported that trilostane is effective in controlling clinical signs in dogs with PDH, with a median survival of 662 days. (3) A study by Fracassi et al. (2015) compared trilostane and mitotane and found similar efficacy but fewer side effects with trilostane. (4) For cats with acromegaly, a study by Niessen et al. (2015) showed that radiation therapy improves survival and glycemic control. (5) A study by Hanson et al. (2007) demonstrated that MRI is highly sensitive for detecting pituitary macroadenomas. (6) The European Society of Veterinary Endocrinology (ESVE) has published guidelines for the management of pituitary tumors. (7) A meta-analysis by Bennaim et al. (2019) confirmed that trilostane is safe and effective for long-term management of PDH. (8) For surgical hypophysectomy, a study by Meij et al. (2002) reported successful outcomes in dogs with microadenomas, with a 5-year survival rate of 80%.